Robert J Foglesong

USPTO Granted Patents = 15 (Patent Applications = 5)

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 8.0

ph-index = 4

Forward Citations = 61(Granted Patents)

Company Filing History:

Eli Lilly and Company

Years Active: 2000-2019

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10183935 - Benzamide derivatives as modulators of the follicle stimulating hormone (2019-01-22),

2. 9775830 - Dihydropyrazoles (2017-10-03),

3. 9708321 - Spiro-quinazolinone derivatives and their use as positive allosteric modulators of mGluR4 (2017-07-18),

4. 9517227 - Dihydropyrazoles (2016-12-13),

5. 9409897 - Benzamide derivatives as modulators of the follicle stimulating hormone (2016-08-09),

6. 8791114 - Dihydropyrazoles (2014-07-29),

7. 7902252 - Inhibitors of D-amino acid oxidase (2011-03-08),

8. 7884124 - Fluoro-substituted inhibitors of D-amino acid oxidase (2011-02-08),

9. 7842707 - Peptidase inhibitors (2010-11-30),

10. 7579370 - Fused heterocycles (2009-08-25),

11. 6541499 - Antithrombotic agents (2003-04-01),

12. 6391901 - Thrombin inhibitors (2002-05-21),

13. 6350774 - Antithrombotic agents (2002-02-26),

14. 6251921 - Antithrombotic diamines (2001-06-26),

15. 6025382 - Antithrombotic diamines (2000-02-15),

Title: The Innovative Contributions of Robert J Foglesong

Introduction

Robert J Foglesong is a prominent inventor based in Durham, NC, known for his significant contributions to the field of pharmaceuticals. With a total of 15 patents to his name, he has made remarkable advancements, particularly in the treatment of fertility disorders.

Latest Patents

Among his latest patents are novel benzamide derivatives that act as positive allosteric modulators of the follicle-stimulating hormone (FSH) receptor. These compounds can be employed for the treatment of fertility disorders. Additionally, he has developed novel dihydropyrazole derivatives, which also serve as positive allosteric modulators of the FSH receptor, further contributing to potential fertility treatments.

Career Highlights

Throughout his career, Robert has worked with notable companies such as Merck Patent GmbH and Eli Lilly and Company. His work in these organizations has allowed him to develop innovative solutions that address critical health issues.

Collaborations

Robert has collaborated with esteemed colleagues, including Thomas E Richardson and Nickolay Y Chirgadze, enhancing the scope and impact of his research.

Conclusion

Robert J Foglesong's contributions to the field of pharmaceuticals, particularly in fertility treatments, highlight his innovative spirit and dedication to improving health outcomes. His work continues to influence the industry and inspire future advancements.

This text is generated by artificial intelligence and may not be accurate.